Monoclonal antibody hNM01 in HIV-infected patients: A phase I study

Journal of Clinical Virology

Volumn 31, Issue SUPPL. 1, 2004, Pages

  Dezube, Bruce J ^a   Doweiko, John P ^a   Proper, Jo Ann ^a   Conway, Brian ^b   Hwang, Liana ^b   Terada, Masaki ^c   Leece, Barbara A ^d   Ohno, Tsuneya ^e   Mastico, Robert A ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Shiga 525 0055   (Japan)

^d IMMUNOGEN INC   (United States)

^e JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical study; HIV infection; Humanized monoclonal antibody

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HNMO1; UNCLASSIFIED DRUG;

ARTICLE; CELL COUNT; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOTENSION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; VIRION; VIRUS ENVELOPE; VIRUS LOAD;

ANTIBODIES, MONOCLONAL; COMPLEMENT ACTIVATION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; SAFETY;

EID: 9644301012     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2004.09.003     Document Type: Article

References (10)

1. C. Armbruster, G. Stiegler, B. Vcelar, W. Jager, N. Michael, N. Vetter, and H. Katinger A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV 1 AIDS 16 2002 227 233
2. R. Cantin, G. Martin, and M.J. Tremblay A novel virus capture assay reveals a differential acquisition of host HLA-DR by clinical isolates of human immunodeficiency virus type I expanded in primary human cells depending on the nature of producing cells and the donor source J General Virol 82 2001 2979 2987
3. J.D. Isaacs, R.A. Watts, and B.L. Hazleman Humanised monoclonal antibody therapy for rheumatoid arthritis Lancet 340 1992 748 752
4. R.P. Junghans, G. Sgouros, and D.A. Scheinberg Antibody-based immunotherapies for cancer B. Chabner DL. Longo Cancer chemotherapy and biotherapy 2nd ed.< 1996 Lippincott-Raven Publishers Philadelphia
5. A.F. LoBuglio, R.H. Wheeler, J. Trang, A. Haynes, K. Rogers, E.B. Harvey, L. Sun, J. Ghrayeb, and M.B. Kazaeli Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response Proc Natl Acad Sci USA 86 1989 4220 4224
6. M. Nakamura, M. Terada, H. Sasaki, M. Kamada, and T. Ohno Virolysis and in vitro neutralization of HIV-1 by humanized monoclonal antibody hNM-01 Hybridoma 19 2000 427 434
7. M. Nakamura, H. Sasaki, and M. Terada Complement-dependent virolysis of HIV-1 with monoclonal antibody NM-01 AIDS Res Hum Retrovir 9 1993 619 626
8. T. Ohno, M. Terada, and Y. Yoneda A broadly neutralizing monoclonal antibody that recognizes the V3 region of human immunodeficiency virus type 1 glycoprotein gp120 Proc Natl Acad Sci USA 88 1991 10726 10729
9. M.A. Sande, C.C. Carpenter, C.G. Cobbs, K.K. Holmes, and J.P. Sanford Antiretroviral therapy for adult HIV-infected patients. Recommendations from a state-of-the-art conference. National Institute of Allergy and Infectious Diseases State-of-the-Art Panel on Anti Retroviral Therapy for Adult HIV-Infected Patients JAMA 270 1993 2583 3589
10. K. Yoshida, M. Nakamura, and T. Ohno Mutations of the HIV type 1 V3 loop under selection pressure with neutralizing monoclonal antibody NM-01 AIDS Res Hum Retrovir 13 1997 1283 1290